Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30849215 | 0.91 | PARP10 (0.42) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL248077 | 0.88 | LMNA (0.59) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| Trifluoroacetic Acid SCHEMBL29489200 | 0.87 | LMNA (0.43) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL28446692 | 0.84 | LMNA (0.55) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL28446693 | 0.82 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL28659060 | 0.82 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL248078 | 0.80 | NPC1 (0.56) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL30790800 | 0.80 | LMNA (0.52) | LMNACYP1A2CYP3A4MAOAPARP10 | |
| SCHEMBL9994271 | 0.80 | RAB9A (0.58) | LMNATSHRNPC1RAB9AMAPT | |
| SCHEMBL27525468 | 0.80 | TDP1 (0.59) | LMNACYP1A2PRSS1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025188678-A9 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250288611-A1 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. | 2025-09-18 | — | — | US | claimed |
| US-20230144142-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | McSAF Inside Oncology (FR) | 2023-05-11 | — | — | US | claimed |
| CN-115515642-A | anti-CD 56 antibody-drug conjugates and their use in therapy | 麦克萨夫内部肿瘤公司 | 2022-12-23 | — | — | CN | claimed |
| EP-3464294-B1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OUE (EE) | 2022-07-13 | — | — | EP | claimed |
| WO-2025188678-A9 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250288611-A1 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. | 2025-09-18 | — | — | US | disclosed |
| US-20230405140-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | McSAF Inside Oncology (FR) | 2023-12-21 | — | — | US | disclosed |
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | MC SAF (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-116472268-A | Compounds capable of binding to proteins and conjugates obtained from these compounds | MC SAF公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4181964-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | Mc SAF (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-20230144142-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | McSAF Inside Oncology (FR) | 2023-05-11 | — | — | US | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9732367-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| CN-105026574-A | Cell lines | MEDIMMUNE LLC | 2015-11-04 | — | — | CN | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| EP-2898085-A1 | CELL LINES | MedImmune Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014044872-A1 | CELL LINES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011083304-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | SHBG, SERPINA6, F13B | LMNA 3421/4885CYP1A2 2263/4885CYP3A4 2604/4885 |
| US-20150259721-A1 | CELL LINES | AARS1, LARS1, IARS1 | LMNA 2048/4885CYP1A2 4794/4885CYP3A4 4775/4885 |
| US-20230144142-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CD47, NCL, EPCAM | LMNA 1464/4885CYP1A2 4236/4885CYP3A4 3893/4885 |
| US-20230405140-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CD47, NCL, EPCAM | LMNA 1464/4885CYP1A2 4236/4885CYP3A4 3893/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | LMNA 4680/4885CYP1A2 24/4885CYP3A4 16/4885 |
| US-20170306381-A1 | CELL LINES | AARS1, LARS1, IARS1 | LMNA 2048/4885CYP1A2 4794/4885CYP3A4 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.